Publications by authors named "Hakim Bouterfa"

Claim this Profile
[
[Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with F[FDG] PET Imaging.
Ismaheel O Lawal, Gbenga O Popoola, Johncy Mahapane, Jens Kaufmann, Cindy Davis, Hakim Bouterfa

Biomolecules· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Biodistribution, and Radiation Dosimetry of Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
Guillaume P Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman

J Nucl Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity Comparison of Ga-OPS202 and Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
Guillaume P Nicolas, Nils Schreiter, Felix Kaul, John Uiters, Hakim Bouterfa

J Nucl Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution, Pharmacokinetics, and Dosimetry of Lu-, Y-, and In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist Lu-DOTATATE: The Mass Effect.
Guillaume P Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa

J Nucl Med· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model.
Seval Beykan, Jan S Dam, Uta Eberlein, Jens Kaufmann, Benedict Kjærgaard, Hakim Bouterfa

EJNMMI Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
David L Bushnell, Thomas M O'Dorisio, M Sue O'Dorisio, Yusuf Menda, Rodney J Hicks, Hakim Bouterfa

J Clin Oncol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Annamaria Colao, Paolo Cappabianca, Philippe Caron, Ernesto De Menis, Andrew J Farrall, Hakim Bouterfa

Clin Endocrinol (Oxf)· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Moises Mercado, Fatima Borges, Hakim Bouterfa, Tien-Chun Chang, Alberto Chervin

Clin Endocrinol (Oxf)· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Roelf Valkema, Stanislas Pauwels, Larry K Kvols, Raffaella Barone, Francois Jamar, Hakim Bouterfa

Semin Nucl Med· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles.
Beatrice Astruc, Peter Marbach, Hakim Bouterfa, Caroline Denot, Mitra Safari

J Clin Pharmacol· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Andreas Helisch, Gregor J Förster, Helmut Reber, Hans-Georg Buchholz, Rudolf Arnold, Hakim Bouterfa

Eur J Nucl Med Mol Imaging· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues.
Raffaella Barone, Stanislas Pauwels, Joëlle De Camps, Eric P Krenning, Larry K Kvols, Hakim Bouterfa

Nephrol Dial Transplant· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
David Bushnell, Yusuf Menda, Thomas O'Dorisio, Mark Madsen, Sara Miller, Hakim Bouterfa

Cancer Biother Radiopharm· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.
David Bushnell, Thomas O'Dorisio, Yusuf Menda, Thomas Carlisle, Pamela Zehr, Hakim Bouterfa

J Nucl Med· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
David Bushnell, Yusuf Menda, Mark Madsen, Thomas O'Dorisio, Thomas Carlisle, Hakim Bouterfa

Cancer Biother Radiopharm· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
François Jamar, Raffaella Barone, Isabelle Mathieu, Stéphan Walrand, Daniel Labar, Hakim Bouterfa

Eur J Nucl Med Mol Imaging· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis